BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315
29302 results:

  • 1. Integrated Epigenetic and Transcriptomic Analysis Identifies
    Brockman QR; Rytlewski JD; Milhem M; Monga V; Dodd RD
    JCO Precis Oncol; 2024 May; 8():e2300325. PubMed ID: 38820476
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Lumbar functional evaluation of pelvic bone sarcomas after surgical resection and spinal pelvic fixation: A clinical study of 304 cases.
    Shi Q; Guo W; Ji T; Tang X
    Cancer Med; 2024 Jun; 13(11):e7282. PubMed ID: 38819113
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Translational Potential of Baicalein in Mitigating RSL3-Induced Ferroptosis in Fibroblasts: Implications for Therapeutic Interventions.
    Kuo PJ; Rau CS; Wu YC; Tsai CW; Wu CJ; Lin CW; Hsieh CH
    Int J Med Sci; 2024; 21(7):1257-1264. PubMed ID: 38818460
    [No Abstract]    [Full Text] [Related]  

  • 4. A novel nomogram and prognostic factor for metastatic soft tissue sarcoma survival.
    Han D; Li B; Xu J; Hu Y; Chen X; Wang R
    Front Endocrinol (Lausanne); 2024; 15():1371910. PubMed ID: 38803474
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. EFHD1 promotes osteosarcoma proliferation and drug resistance by inhibiting the opening of the mitochondrial membrane permeability transition pore (mPTP) by binding to ANT3.
    Shen X; Ma M; Mi R; Zhuang J; Song Y; Yang W; Li H; Lu Y; Yang B; Liu Y; Wu Y; Shen H
    Cell Mol Life Sci; 2024 May; 81(1):236. PubMed ID: 38795203
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
    Ham JM; Kim M; Kim T; Ryu SE; Park H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A Two-Step Approach to the Surgical Treatment of Soft-Tissue sarcomas.
    Fulchignoni C; Cianni L; Matrangolo MR; Cerrone M; Cavola F; Pataia E; Vitiello R; Maccauro G; Farsetti P; Rovere G
    Curr Oncol; 2024 May; 31(5):2805-2816. PubMed ID: 38785494
    [No Abstract]    [Full Text] [Related]  

  • 8. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
    Wood GE; Meyer C; Petitprez F; D'Angelo SP
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeted PLK1 suppression through RNA interference mediated by high-fidelity Cas13d mitigates osteosarcoma progression via TGF-β/Smad3 signalling.
    Yuan Y; Cao D; Zhang A; Liu Z; Deng Z; Zhang S
    J Cell Mol Med; 2024 May; 28(10):e18400. PubMed ID: 38780513
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy.
    Torrado C; Baysal MA; Chakraborty A; Norris BL; Khawaja F; Tsimberidou AM
    Front Immunol; 2024; 15():1366271. PubMed ID: 38779675
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A population-based study on incidence trends of kidney and renal pelvis cancers in the United States over 2000-2020.
    Mousavi SE; Najafi M; Aslani A; Fazlollahi A; Yekta Z; Sadri M; Nejadghaderi SA
    Sci Rep; 2024 May; 14(1):11294. PubMed ID: 38760399
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Correlations between the modification patterns mediated by pyroptosis-related genes, tumor microenvironment, and immunotherapy in soft tissue sarcoma.
    Cai Y; Meng J; Qiu Y; Huang X; Du H; Yao J
    Medicine (Baltimore); 2024 May; 103(20):e38173. PubMed ID: 38758862
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on sarcomas (GEIS) study.
    Moura DS; Mondaza-Hernandez JL; Sanchez-Bustos P; Peña-Chilet M; Cordero-Varela JA; Lopez-Alvarez M; Carrillo-Garcia J; Martin-Ruiz M; Romero-Gonzalez P; Renshaw-Calderon M; Ramos R; Marcilla D; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ortega-Medina L; Martin-Davila F; Hernandez-Leon CN; Romagosa C; Salgado MAV; Lavernia J; Bagué S; Mayodormo-Aranda E; Alvarez R; Valverde C; Martinez-Trufero J; Castilla-Ramirez C; Gutierrez A; Dopazo J; Hindi N; Garcia-Foncillas J; Martin-Broto J
    Cell Mol Life Sci; 2024 May; 81(1):219. PubMed ID: 38758230
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
    Nasri E; Torrence DE; Vasilopoulos T; Knapik JA; Lagmay JP; Reith JD; Gibbs CP
    Cancer J; 2024 May-Jun 01; 30(3):133-139. PubMed ID: 38753746
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.
    Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickström SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
    Sci Transl Med; 2024 May; 16(747):eadi2952. PubMed ID: 38748775
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Imaging characteristics and diagnosis of primary middle mediastinal tumors].
    Chen JQ; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):449-456. PubMed ID: 38742358
    [No Abstract]    [Full Text] [Related]  

  • 19. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC.
    Brazel D; Nagasaka M
    Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours.
    Zago Baltazar R; Claerhout S; Vander Borght S; Spans L; Sciot R; Schöffski P; Hompes D; Sinnaeve F; Wafa H; Renard M; van den Hout MF; Vernemmen A; Libbrecht L; De Roo AK; Mazzeo F; van Marcke C; Deraedt K; Bourgain C; Vanden Bempt I
    J Pathol Clin Res; 2024 May; 10(3):e12376. PubMed ID: 38738521
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1466.